AMEDISYS INC (AMED) Stock Fundamental Analysis

NASDAQ:AMED • US0234361089

100.99 USD
+0.01 (+0.01%)
At close: Aug 14, 2025
100.99 USD
0 (0%)
After Hours: 8/14/2025, 8:02:42 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

AMED gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. AMED has an excellent profitability rating, but there are some minor concerns on its financial health. AMED has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year AMED was profitable.
  • In the past year AMED had a positive cash flow from operations.
  • Of the past 5 years AMED 4 years were profitable.
  • Each year in the past 5 years AMED had a positive operating cash flow.
AMED Yearly Net Income VS EBIT VS OCF VS FCFAMED Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

1.2 Ratios

  • AMED has a better Return On Assets (3.87%) than 72.12% of its industry peers.
  • The Return On Equity of AMED (6.95%) is better than 66.35% of its industry peers.
  • AMED has a better Return On Invested Capital (10.34%) than 81.73% of its industry peers.
  • AMED had an Average Return On Invested Capital over the past 3 years of 9.73%. This is in line with the industry average of 8.98%.
  • The 3 year average ROIC (9.73%) for AMED is below the current ROIC(10.34%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.87%
ROE 6.95%
ROIC 10.34%
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
AMED Yearly ROA, ROE, ROICAMED Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10 15 20

1.3 Margins

  • AMED has a better Profit Margin (3.56%) than 68.27% of its industry peers.
  • AMED's Profit Margin has declined in the last couple of years.
  • The Operating Margin of AMED (9.41%) is better than 78.85% of its industry peers.
  • In the last couple of years the Operating Margin of AMED has remained more or less at the same level.
  • Looking at the Gross Margin, with a value of 43.19%, AMED is in the better half of the industry, outperforming 71.15% of the companies in the same industry.
  • In the last couple of years the Gross Margin of AMED has remained more or less at the same level.
Industry RankSector Rank
OM 9.41%
PM (TTM) 3.56%
GM 43.19%
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
AMED Yearly Profit, Operating, Gross MarginsAMED Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMED is still creating some value.
  • The number of shares outstanding for AMED has been increased compared to 1 year ago.
  • AMED has more shares outstanding than it did 5 years ago.
  • AMED has a better debt/assets ratio than last year.
AMED Yearly Shares OutstandingAMED Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
AMED Yearly Total Debt VS Total AssetsAMED Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 4.10 indicates that AMED is not in any danger for bankruptcy at the moment.
  • AMED has a Altman-Z score of 4.10. This is in the better half of the industry: AMED outperforms 75.00% of its industry peers.
  • AMED has a debt to FCF ratio of 1.55. This is a very positive value and a sign of high solvency as it would only need 1.55 years to pay back of all of its debts.
  • AMED has a better Debt to FCF ratio (1.55) than 85.58% of its industry peers.
  • AMED has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.26, AMED is in the better half of the industry, outperforming 65.38% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 1.55
Altman-Z 4.1
ROIC/WACC1.2
WACC8.61%
AMED Yearly LT Debt VS Equity VS FCFAMED Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.3 Liquidity

  • AMED has a Current Ratio of 1.36. This is a normal value and indicates that AMED is financially healthy and should not expect problems in meeting its short term obligations.
  • AMED has a Current ratio (1.36) which is in line with its industry peers.
  • AMED has a Quick Ratio of 1.36. This is a normal value and indicates that AMED is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of AMED (1.36) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.36
Quick Ratio 1.36
AMED Yearly Current Assets VS Current LiabilitesAMED Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • AMED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.24%, which is quite good.
  • Measured over the past years, AMED shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.46% on average per year.
  • The Revenue has been growing slightly by 4.93% in the past year.
  • Measured over the past years, AMED shows a small growth in Revenue. The Revenue has been growing by 3.73% on average per year.
EPS 1Y (TTM)11.24%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%16.67%
Revenue 1Y (TTM)4.93%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%5.19%

3.2 Future

  • The Earnings Per Share is expected to grow by 6.47% on average over the next years.
  • AMED is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.95% yearly.
EPS Next Y13.17%
EPS Next 2Y10.6%
EPS Next 3Y6.47%
EPS Next 5YN/A
Revenue Next Year4.17%
Revenue Next 2Y4.73%
Revenue Next 3Y4.95%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AMED Yearly Revenue VS EstimatesAMED Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B 2B 2.5B
AMED Yearly EPS VS EstimatesAMED Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • AMED is valuated rather expensively with a Price/Earnings ratio of 21.26.
  • 67.31% of the companies in the same industry are more expensive than AMED, based on the Price/Earnings ratio.
  • AMED is valuated rather cheaply when we compare the Price/Earnings ratio to 27.19, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 19.15, which indicates a rather expensive current valuation of AMED.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of AMED indicates a somewhat cheap valuation: AMED is cheaper than 62.50% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.06. AMED is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 21.26
Fwd PE 19.15
AMED Price Earnings VS Forward Price EarningsAMED Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • AMED's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. AMED is cheaper than 65.38% of the companies in the same industry.
  • AMED's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. AMED is cheaper than 78.85% of the companies in the same industry.
Industry RankSector Rank
P/FCF 14.18
EV/EBITDA 11.63
AMED Per share dataAMED EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

  • AMED's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The decent profitability rating of AMED may justify a higher PE ratio.
PEG (NY)1.61
PEG (5Y)N/A
EPS Next 2Y10.6%
EPS Next 3Y6.47%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • AMED does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

AMEDISYS INC

NASDAQ:AMED (8/14/2025, 8:02:42 PM)

After market: 100.99 0 (0%)

100.99

+0.01 (+0.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)07-29
Earnings (Next)11-04
Inst Owners92.54%
Inst Owner Change-92.65%
Ins Owners1.88%
Ins Owner Change0%
Market Cap3.32B
Revenue(TTM)2.40B
Net Income(TTM)85.63M
Analysts54.12
Price Target102.87 (1.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.78%
Min EPS beat(2)12.12%
Max EPS beat(2)13.43%
EPS beat(4)2
Avg EPS beat(4)-0.15%
Min EPS beat(4)-15.99%
Max EPS beat(4)13.43%
EPS beat(8)3
Avg EPS beat(8)-1.75%
EPS beat(12)6
Avg EPS beat(12)2.15%
EPS beat(16)9
Avg EPS beat(16)3.64%
Revenue beat(2)1
Avg Revenue beat(2)-1.09%
Min Revenue beat(2)-2.2%
Max Revenue beat(2)0.01%
Revenue beat(4)1
Avg Revenue beat(4)-1.56%
Min Revenue beat(4)-2.2%
Max Revenue beat(4)0.01%
Revenue beat(8)2
Avg Revenue beat(8)-1.41%
Revenue beat(12)2
Avg Revenue beat(12)-2.17%
Revenue beat(16)2
Avg Revenue beat(16)-2.65%
PT rev (1m)0%
PT rev (3m)0.02%
EPS NQ rev (1m)7.75%
EPS NQ rev (3m)3.52%
EPS NY rev (1m)0%
EPS NY rev (3m)0.36%
Revenue NQ rev (1m)0.63%
Revenue NQ rev (3m)-0.23%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.48%
Valuation
Industry RankSector Rank
PE 21.26
Fwd PE 19.15
P/S 1.38
P/FCF 14.18
P/OCF 13.87
P/B 2.69
P/tB N/A
EV/EBITDA 11.63
EPS(TTM)4.75
EY4.7%
EPS(NY)5.27
Fwd EY5.22%
FCF(TTM)7.12
FCFY7.05%
OCF(TTM)7.28
OCFY7.21%
SpS73.04
BVpS37.47
TBVpS-1.84
PEG (NY)1.61
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 3.87%
ROE 6.95%
ROCE 13.09%
ROIC 10.34%
ROICexc 12.85%
ROICexgc 184.87%
OM 9.41%
PM (TTM) 3.56%
GM 43.19%
FCFM 9.75%
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
ROICexc(3y)10.87%
ROICexc(5y)12.42%
ROICexgc(3y)283.58%
ROICexgc(5y)337.19%
ROCE(3y)12.32%
ROCE(5y)14.48%
ROICexgc growth 3Y57.65%
ROICexgc growth 5Y52.31%
ROICexc growth 3Y-5.72%
ROICexc growth 5Y-4.31%
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
F-Score6
Asset Turnover1.08
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 1.55
Debt/EBITDA 1.13
Cap/Depr 8.5%
Cap/Sales 0.22%
Interest Coverage 8.42
Cash Conversion 83.2%
Profit Quality 273.49%
Current Ratio 1.36
Quick Ratio 1.36
Altman-Z 4.1
F-Score6
WACC8.61%
ROIC/WACC1.2
Cap/Depr(3y)21.03%
Cap/Depr(5y)20.63%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.24%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%16.67%
EPS Next Y13.17%
EPS Next 2Y10.6%
EPS Next 3Y6.47%
EPS Next 5YN/A
Revenue 1Y (TTM)4.93%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%5.19%
Revenue Next Year4.17%
Revenue Next 2Y4.73%
Revenue Next 3Y4.95%
Revenue Next 5YN/A
EBIT growth 1Y8.08%
EBIT growth 3Y-8.39%
EBIT growth 5Y3.2%
EBIT Next Year19.91%
EBIT Next 3Y9.46%
EBIT Next 5YN/A
FCF growth 1Y132.55%
FCF growth 3Y5.56%
FCF growth 5Y2%
OCF growth 1Y110.02%
OCF growth 3Y5.48%
OCF growth 5Y1.88%

AMEDISYS INC / AMED FAQ

Can you provide the ChartMill fundamental rating for AMEDISYS INC?

ChartMill assigns a fundamental rating of 5 / 10 to AMED.


Can you provide the valuation status for AMEDISYS INC?

ChartMill assigns a valuation rating of 5 / 10 to AMEDISYS INC (AMED). This can be considered as Fairly Valued.


Can you provide the profitability details for AMEDISYS INC?

AMEDISYS INC (AMED) has a profitability rating of 7 / 10.


What is the valuation of AMEDISYS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for AMEDISYS INC (AMED) is 21.26 and the Price/Book (PB) ratio is 2.69.


What is the financial health of AMEDISYS INC (AMED) stock?

The financial health rating of AMEDISYS INC (AMED) is 6 / 10.